Article Sidebar
Views pdf: 112
OUTCOMES IN PATIENTS WITH ASTHMA–COPD OVERLAP RECEIVING TRIPLE THERAPY AT CAN THO CENTRAL GENERAL HOSPITAL
Main Article Content
Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) and coexisting asthma, referred to as asthma-COPD overlap (ACO), are more likely to experience acute respiratory events than those with COPD alone. This group benefits significantly from treatment regimens that include inhaled corticosteroids; however, the potential benefits must be weighed against the risk of adverse effects. Objective: To evaluate the treatment outcomes of triple therapy in patients with asthma–COPD overlap. Subject and methods: An uncontrolled interventional study was conducted on 40 patients with ACO at Can Tho Central General Hospital, with a follow-up period of 3 months. Results: Patients receiving triple therapy had a median of 3 moderate-to-severe exacerbations in the past year; 40% had at least one exacerbation requiring hospitalization, and 90% had elevated blood eosinophil counts. After 3 months of treatment, all patients showed improvement in symptoms, FEV1, and mMRC scores. Notably, no cases of pneumonia were reported. The mean FEV1 improvement was 7.8% (95% CI: 4.3–11.3; p < 0.001). Conclusion: Triple therapy improves lung function and exercise tolerance in patients with asthma–COPD overlap. Careful patient selection, especially those with a low risk of infection, is essential to minimize adverse effects.
Article Details
Keywords
Asthma-COPD overlap, triple therapy
References
2. Phùng Thị Thanh, Chu Thị Hạnh, Trần Thị Nương (2022). "Một số yếu tố nguy cơ gây đợt cấp thường xuyên ở bệnh nhân có đợt cấp bệnh phổi tắc nghẽn mạn tính nhập viện tại Trung tâm Hô hấp, Bệnh viện Bạch Mai", Tạp chí Y học Việt Nam, 514(1), tr. 100-104.
3. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076–1084.
4. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/ glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6: 747–758.
5. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once daily triple therapy in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671–1680.
6. Van Tho N, Phan TP, Dinh-Xuan AT, et al. COPD Patients with Asthma Features in Vietnam: Prevalence and Suitability for Personalized Medicine. J. Pers. Med. 2023, 13, 901. hĴps://doi.org/10.3390/jpm13060901.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy For The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2023 Report). Available online: h p://www.gold copd.org/ (accessed on 15 November 2022).